



FINAL REPORT

**Sino-implant (II) Initiative: 2015 Quality Assurance Evaluation**

December 15, 2015

Submitted by:

FHI 360

---

Markus Steiner, Ph.D.  
Contraceptive Technology Innovation  
359 Blackwell Street, Suite 200  
Durham, NC 27701  
E-mail: [msteiner@fhi360.org](mailto:msteiner@fhi360.org)  
Telephone: 919-544-7040 ext. 11346  
Fax: 919-544-7261

# Final Report

## Sino-implant (II): 2015 Quality Assurance Evaluation

FHI 360

**Markus Steiner, Ph.D.**

**Sino-implant (II) Project Director**

Contraceptive Technology Innovation

359 Blackwell Street, Suite 200

Durham, NC 27701

E-mail: [msteiner@fhi360.org](mailto:msteiner@fhi360.org)

Telephone: 919-544-7040 ext. 11346

Fax: 919-544-7261

**Derek H. Owen, Ph.D.**

**Scientist I**

Contraceptive Technology Innovation

359 Blackwell Street, Suite 200

Durham, NC 27701

E-mail: [dowen@fhi360.org](mailto:dowen@fhi360.org)

Telephone: 919-544-7040 ext. 11168

Fax: 919-544-7261

**Xian Zhong, Ph.D.**

**Research Associate**

Contraceptive Technology Innovation

359 Blackwell Street, Suite 200

Durham, NC 27701

E-mail: [xzhong@fhi360.org](mailto:xzhong@fhi360.org)

Phone: 919-544-7040 ext. 11192

Fax: 919-544-5849

**David W. Jenkins, Ph.D.**

**Associate Director**

Product Quality and Compliance Department

2810 Meridian Parkway, Suite 160

Durham, NC 27713

E-mail: [djenkins@fhi360.org](mailto:djenkins@fhi360.org)

Phone: 919-544-7040 ext. 11617

Fax: 919-544-5849

**Haizhen Meng**

**Research Associate**

Contraceptive Technology Innovation

359 Blackwell Street, Suite 200

Durham, NC 27701

E-mail: [hmeng@fhi360.org](mailto:hmeng@fhi360.org)

Phone: 919-544-7040 ext. 11491

Fax: 919-544-5849

*Confidential*

*Final Report: Sino-implant (II): 2014 Quality Assurance Evaluation  
FHI360*

## Table of Contents

Final Report .....	i
Executive Summary .....	2
Introduction.....	5
Section I: Annual Quality Assurance Monitoring of Sino-implant (II) .....	6
Sino-implant (II) Commercial Lot Release Testing and Verification .....	6
Section II: Annual Quality Assurance Evaluation of Sino-implant (II) .....	8
Levonorgestrel: API Evaluation .....	9
Levonorgestrel CP Evaluation .....	9
Levonorgestrel EP Evaluation .....	12
Sino-implant (II): Finished Pharmaceutical Product Evaluation .....	14
Quality Assurance Lot Release Verification.....	15
Assay, Related Substance and Content Uniformity Evaluation.....	16
Ethylene Oxide Residuals Evaluation.....	17
Inorganic Impurities Evaluation .....	19
Residual Solvents Evaluation .....	21
Bacterial Endotoxin Evaluation .....	22
Cytotoxicity Evaluation .....	23
Sino-implant (II): Packaging Material Evaluation.....	24
Packaging Physicochemical Evaluation .....	24
Package Integrity Evaluation .....	25
Section III: Summary of Results of the 2015 Comprehensive Quality Assurance Evaluation ....	26

## List of Tables

Table 1. Summary of 2015 QA Monitoring and Evaluation of Sino-implant (II).....	4
Table 2. Sino-implant (II) commercial lot release verification test results.....	7
Table 3. Levonorgestrel: lot release verification test results analyzed using the CP monograph. .....	10
Table 4. Levonorgestrel: lot release verification test results analyzed using the EP monograph	12
Table 5. Sino-implant (II) QA lot release verification results. ....	15
Table 6. Assay, related substance and content uniformity results of Sino-implant (II).....	16
Table 7. Ethylene oxide residuals test results of Sino-implant (II).....	18
Table 8. ICP-MS test results of Sino-implant (II): USP <232> inorganic impurities. ....	20
Table 9. ICP-MS test results of Sino-implant (II) Pt .....	20
Table 10. Residual solvents test results of Sino-implant (II).....	21
Table 11. Limulus Amebocyte Lysate (LAL) Test (Kinetic Turbidimetric Technique) test results of Sino-implant (II). ....	22
Table 12. MEM elution test results of Sino-implant (II). ....	23
Table 13. Physicochemical test results of Sino-implant (II) packaging film.....	24
Table 14. Bubble emission test results of Sino-implant (II) packages .....	25
Table 15. Comprehensive tabulated summary of the QA results of Sino-implant (II) tests conducted. ....	26

## List of Abbreviations

API	Active Pharmaceutical Ingredient
ASTM	American Society for Testing and Materials
BLD	Below Limit of Detection
BRL	Below Reporting Limit
BP	British Pharmacopeia
CFDA	China Food and Drug Administration
CP	China Pharmacopeia
Dahua	Dahua Pharmaceutical Co., Ltd
DMF	Dimethylformamide
ECH	Ethylene Chlorohydrin
EG	Ethylene Glycol
EO	Ethylene Oxide
EP	European Pharmacopeia
FPP	Finished Pharmaceutical Product
GC	Gas Chromatography
NMT	No More Than
ICH	International Conference on Harmonisation
ISO	International Organization for Standardization
LAL	Limulus Amebocyte Lysate
LNG	Levonorgestrel
PDE	Permitted Daily Dose
QA	Quality Assurance
TLC	Thin Layer Chromatography
US FDA	U.S. Food and Drug Administration
USP	United States Pharmacopeia
WHO	World Health Organization
Yangzhou	Yangzhou Pharmaceutical Co., Ltd.
ZiZhu	China Resources ZiZhu Pharmaceutical Co., Ltd.

## Executive Summary

A Quality Assurance (QA) Evaluation and Monitoring program was implemented by FHI 360 to verify that Sino-implant (II) meets lot release specifications for the product. This report expands on the results obtained after the QA evaluation and monitoring program conducted from 2008 to 2014.

Commercial lot release testing verification was conducted for two (2) lots of Sino-implant (II), with Active Pharmaceutical Ingredient (API) Levonorgestrel (LNG) supplied by Yangzhou Pharmaceutical Co. Ltd., (Yangzhou) that was shipped to countries as part of the Sino-implant (II) introduction in developing countries. In all instances results were in compliance with Sino-implant (II) lot release specifications (Table 1).

A more extensive battery of tests was conducted to evaluate if Sino-implant (II) meets international quality standards. The battery of tests selected was based on standards from the United States Pharmacopeia (USP), EP European Pharmacopeia (EP), International Organization for Standardization (ISO), and the American Society for Testing and Materials (ASTM), recognized by World Health Organization (WHO) Prequalification (PQ) program.

From 2008 to 2012, LNG test results concluded that Yangzhou API was capable of meeting all LNG standards tested, including China Pharmacopeias (CP), USP and British Pharmacopeias (BP). In 2013, the LNG BP monograph was harmonized with the LNG EP monograph, which resulted in more stringent specifications. The Yangzhou API was unable to meet these more stringent specifications in 2013.

With the aim of obtaining WHO Prequalification (PQ) approval for Sino-implant (II), Shanghai Dahua Pharmaceutical Co., (Dahua), the finished pharmaceutical product (FPP) manufacturer, switched API supplier from Yangzhou to China Resources Zizhu Pharmaceutical Co., Ltd. (ZiZhu) in their WHO PQ application submitted May 2015 2013. The ZiZhu LNG API has been prequalified by WHO (Ref: APIMF172) and is capable of meeting the latest EP standards requested by WHO.

However, since it is the Yangzhou not ZiZhu API currently registered as the API of Sino-implant (II) in all marketed countries, the company will continue using the Yangzhou API for making commercial lots of Sino-implant (II), until the product with the ZiZhu API obtains the WHO PQ approval and is approved at the country level. Therefore, during this transitional period, three (3) lots of the ZiZhu API, purchased for making three (3) lots FPP for WHO-PQ covered countries, and three (3) lots of the Yangzhou API, made for the FPP commercial lots, were selected and evaluated according to the CP 2010 and EP 8.0 LNG monograph in 2015 QA Evaluation program.

Test results concluded that the ZiZhu API was capable of meeting all specifications of LNG CP 2010 and EP 8.0 monograph. The Yangzhou API is continuously capable of meeting specifications of LNG CP 2010 monograph, the legal standard for LNG in China (Table 1).

Additionally, the three (3) FPP lots with Yangzhou API, made by Dahua for China market, were selected and tested for not only the same battery of QA evaluation tests previously conducted, but also some new tests requested by WHO in Dahua's PQ application, including assay and related substances test (HPLC) and content uniformity test. Test results concluded that Sino-implant (II), made of Yangzhou API, are capable of meeting quality requirements for all tests conducted (Table 1).

Furthermore, with an ultimate goal of performing all QA testing in China, an effort was made this year to move some of the QA testing conducted in US to China. In 2014-2015, the following testing were transferred to China, and all test methods were validated by receiving labs prior to the sample testing:

- Ethylene Oxide (EO) Residuals Evaluation, from Nelson to SGS Shanghai
- Residual Solvents Evaluation, from Irvine to SGS Shanghai
- Bacterial Endotoxin Evaluation, from Nelson to SGS Shanghai
- Inorganic Impurities Evaluation, from SGS US to SGS Shanghai
- Packaging Material Physicochemical Properties Evaluation, from Nelson to SGS Shanghai

**Table 1. Summary of 2015 QA Monitoring and Evaluation of Sino-implant (II)**

Test Item	Lot No.	Result	
<b>Annual QA Monitoring of Sino-implant (II)</b>			
Sino-implant (II): Commercial Lot Release Verification (SGS, Shanghai, China)	Lot 20140805 Lot 20150604 (with Yangzhou API)	Met requirements	
<b>Annual QA Evaluation of Sino-implant (II)</b>			
Levonorgestrel (LNG): API QA Evaluation	CP 2010 Evaluation (SGS, Shanghai, China)	ZiZhu Pharmaceutical Co., Ltd. (ZiZhu) Lot S1370801504001 Lot S1370801504002 Lot S1370801504004	Met requirements
		Yangzhou Pharmaceutical Co., Ltd. (Yangzhou) Lot S01ZQ20140007 Lot S01ZQ20150004 Lot S01ZQ20150005	Met requirements
	EP 8.0 Evaluation (SGS, Shanghai, China)	ZiZhu Pharmaceutical Co., Ltd. (ZiZhu) Lot S1370801504001 Lot S1370801504002 Lot S1370801504004	Met requirements
Sino-implant (II) : FPP QA Evaluation	QA Lot Release Verification (SGS, Shanghai, China)	Lot 20150101 Lot 20150402 Lot 20150503	Met requirements
	Assay, Related Substance and Content Uniformity Evaluation (Frontage, Suzhou, China)		Met requirements
	Ethylene Oxide (EO) Residuals Evaluation (SGS Shanghai, China)		Met requirements
	Inorganic Impurities Evaluation (SGS, Shanghai, China)		Met requirements
	Residual Solvents Evaluation (SGS Shanghai, China)		Met requirements
	Bacterial Endotoxin Evaluation (SGS Shanghai, China)		Met requirements
	Cytotoxicity Evaluation (Nelson, Salt Lake City, UT, USA)	Lot 20140805 Lot 20150101 Lot 20150402	Met requirements
Sino-implant (II) : Packaging Material QA Evaluation	Packaging Physicochemical Evaluation (SGS Shanghai, China)	Lot B0107(11-0719)-11-8-23-1 Lot B0106(11-0719A-1)-11-9-22-1 Lot B0111(11-0719A-1)-11-9-22-1	Met requirements
	Package Integrity Evaluation (Nelson Salt Lake City, UT, USA)	Lot 20140805 Lot 20150101 Lot 20150402	Met requirements